Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform
06:07am, Thursday, 12'th Dec 2024
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The r
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
03:14pm, Monday, 09'th Dec 2024
Recursion Pharmaceuticals, Inc. expects to meet with the FDA to discuss the potential of advancing REC-994 for the treatment of patients with cerebral cavernous malformation. REC-1245 is a CDK12-adjac
NVIDIA Invested in These 2 AI Stocks, Should You?
08:37am, Monday, 02'nd Dec 2024
NVIDIA Co. NASDAQ: NVDA is the undisputed leader of the artificial intelligence (AI) revolution. The company envisioned an AI future over 12 years ago and began executing the blueprint for domination.
2 Innovative Stocks That Could Deliver Outsize Returns
10:00am, Friday, 22'nd Nov 2024
2 Innovative Stocks That Could Deliver Outsize Returns
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with
Recursion and Exscientia Shareholders Approve the Proposed Combination
09:08am, Wednesday, 13'th Nov 2024
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden
04:54pm, Tuesday, 12'th Nov 2024
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler OpenPhenom is a non-commercial, publicly av
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
08:01pm, Wednesday, 06'th Nov 2024
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
09:45am, Saturday, 02'nd Nov 2024
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
06:50pm, Friday, 01'st Nov 2024
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $6.40, representing a +1.27% change from its previous close.
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:56pm, Wednesday, 30'th Oct 2024
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.68, signifying a -0.89% move from its prior day's close.
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
08:22am, Wednesday, 30'th Oct 2024
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipat
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
09:00am, Saturday, 26'th Oct 2024
This company stands to benefit from a shifting pharmaceutical industry landscape.
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
06:56pm, Thursday, 24'th Oct 2024
Recursion Pharmaceuticals (RXRX) reachead $6.36 at the closing of the latest trading day, reflecting a +0.47% change compared to its last close.
